Integra LifeSciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides 2021 Financial Guidance

Go back to Integra LifeSciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides 2021 Financial Guidance

Integra LifeSciences (IART) PT Raised to $75 at Truist Securities

February 18, 2021 4:21 PM EST

Truist Securities analyst Kaila Krum raised the price target on Integra LifeSciences (NASDAQ: IART) to $75.00 (from $70.00) while maintaining a Buy rating.

The analyst comments "Integra announced Q4 2020 results, with revenue of $389 million coming in at the high end of its preliminary range that... More

Integra LifeSciences (IART) Tops Q4 EPS by 11c; Offers 1Q EPS/Revenue Guidance Below Consensus, FY21 Revenues Views Below Consensus

February 18, 2021 6:26 AM EST

Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.84, $0.11 better than the analyst estimate of $0.73. Revenue for the quarter came in at $388.6 million versus the consensus estimate of $388.58 million.

Fourth Quarter 2020

Reported revenues were $388.6 million, representing a decrease of 1.6% on a reported basis and a decrease of 1.5% on an organic basis compared to the fourth quarter 2019.Fourth quarter revenues increased 5.0% compared to the third quarter of 2020.GAAP earnings per diluted share were $1.09, compared to $0.18 in the fourth quarter 2019.Adjusted earnings per diluted share were $0.84, compared to... More